EMEmmanuelle J. Meuillet

Emmanuelle J. Meuillet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emmanuelle J. Meuillet has a total of 246 co-authors. Here are the top co-authors by number of shared publications:

  • Garth Powis

    MD Anderson Cancer Center, Houston, TX

    12 shared publications
  • Zuohe Song

    Departments of Nutritional Sciences and Molecular and Cellular Biology, the University of Arizona Cancer Center, Tucson, Arizona, United States of America

    9 shared publications
  • Lei Du-Cuny

    Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America

    8 shared publications
  • Sylvestor A. Moses

    University of Arizona Cancer Center, Tucson, AZ

    8 shared publications
  • Shuxing Zhang

    Experimental Therapeutics Department, University of Texas M. D. Anderson Cancer Center, Houston, TX 77054, USA

    6 shared publications
  • Vijay Gokhale

    Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ

    6 shared publications

Latest Publications

  • Open Access

    Preclinical Studies of MVT-100, A Novel Ultrasound Enhancing Agent

    by Emmanuelle J. Meuillet, Joel Lusk, Holly Tadevich, Jonathan R. Lindner, Soheb Anwar Mohammed, Benay Ozbay, Muhammad Wahab Amjad, John J. Pacella, Xucai Chen, Leyla E. Sade, et al.

  • Open Access

    Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting

    by Mark Steven Miller, Peter J. Allen, Powel H. Brown, Andrew T. Chan, Margie L. Clapper, Roderick H. Dashwood, Shadmehr Demehri, Mary L. Disis, Raymond N. DuBois, Robert J. Glynn, et al.

    Mark Steven Miller, Peter J. Allen, Powel H. Brown, Andrew T. Chan, Margie L. Clapper, Roderick H. Dashwood, Shadmehr Demehri, Mary L. Disis, Raymond N. DuBois, Robert J. Glynn, Thomas W. Kensler, Seema A. Khan, Bryon D. Johnson, Karen T. Liby, Steven M. Lipkin, Susan R. Mallery, Emmanuelle J. Meuillet, Richard B.S. Roden, Robert E. Schoen, Zelton D. Sharp, Haval Shirwan, Jill M. Siegfried, Chinthalapally V. Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed. J Cancer Prev 2021;26:71-82. https://doi.org/10.15430/JCP.2021.26.1.71


  • Open Access

    Submolecular regulation of cell transformation by deuterium depleting water exchange reactions in the tricarboxylic acid substrate cycle

    by László G. Boros, Dominic P. D’aGostino, Howard E. Katz, Justine P. Roth, Emmanuelle J. Meuillet, Gábor Somlyai


  • Top Cited Papers
    Open Access

    A roadmap for interpreting 13 C metabolite labeling patterns from cells

    by Joerg M Buescher, Maciek R Antoniewicz, Laszlo G Boros, Shawn C Burgess, Henri Brunengraber, Clary B Clish, Ralph J DeBerardinis, Olivier Feron, Christian Frezza, Bart Ghesquiere, et al.


  • Open Access

    Novel Inhibitors Induce Large Conformational Changes of GAB1 Pleckstrin Homology Domain and Kill Breast Cancer Cells

    by Lu Chen, Lei Du-Cuny, Sylvestor Moses, Sabrina Dumas, Zuohe Song, Abdol Hossein Rezaeian, Hui-Kuan Lin, Emmanuelle J. Meuillet, Shuxing Zhang

    The Grb2-associated binding protein 1 (GAB1) integrates signals from different signaling pathways and is over-expressed in many cancers, therefore representing a new therapeutic target. In the present study, we aim to target the pleckstrin homology (PH) domain of GAB1 for cancer treatment. Using homology models we derived, high-throughput virtual screening of five million compounds resulted in five hits which exhibited strong binding affinities to GAB1 PH domain. Our prediction of ligand binding affinities is also in agreement with the experimental KD values. Furthermore, molecular dynamics studies showed that GAB1 PH domain underwent large conformational changes upon ligand binding. Moreover, these hits inhibited the phosphorylation of GAB1 and demonstrated potent, tumor-specific cytotoxicity against MDA-MB-231 and T47D breast cancer cell lines. This effort represents the discovery of first-in-class GAB1 PH domain inhibitors with potential for targeted breast cancer therapy and provides novel insights into structure-based approaches to targeting this protein. In this paper, we described the identification and evaluation of a set of first-in-class potent inhibitors targeting a new cancer target, Grb2-associated binder-1 (GAB1), which integrates signals from different signaling pathways, and is frequently over-expressed in cancer cells. To achieve our goals, we have employed intensive computational modeling to understand the structure of the GAB1 pleckstrin homology (PH) domain and screened five million compounds. Upon biological evaluation, we found that several inhibitors that induced large conformational changes of the target structure exhibited strong selective binding to GAB1 PH domain. Particularly, these inhibitors demonstrated potent and tumor-specific cytotoxicity in breast cancer cells. This represents a groundbreaking discovery in targeting GAB1 signaling which may be used for cancer therapy, especially for triple negative breast cancer patients.


  • Open Access

    Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer

    by Mark D Pagel, Justin J Jeffery, Edward R Abril, Raymond B Nagle, Roberto Guzman, Emmanuelle J Meuillet, Armando Lucero-Acuna

    Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer Armando Lucero-Acuña,1 Justin J Jeffery,2 Edward R Abril,3,4 Raymond B Nagle,3,4 Roberto Guzman,1 Mark D Pagel,2,3,5,6 Emmanuelle J Meuillet3,7,8 1Department of Chemical and Environmental Engineering, University of Arizona, 2Department of Biomedical Engineering, University of Arizona, 3University of Arizona Cancer Center, 4Department of Pathology, University of Arizona, 5Department of Chemistry and Biochemistry, University of Arizona, 6Department of Medical Imaging, University of Arizona, 7Department of Molecular and Cell Biology, University of Arizona, 8Department of Nutritional Sciences, University of Arizona, Tucson, AZ, USA The K-ras mutation in pancreatic cancer can inhibit drug delivery and increase drug resistance. This is exemplified by the therapeutic effect of PH-427, a small molecule inhibitor of AKT/PDK1, which has shown a good therapeutic effect against a BxPC3 pancreatic cancer model that has K-ras, but has a poor therapeutic effect against a MiaPaCa-2 pancreatic cancer model with mutant K-ras. To increase the therapeutic effect of PH-427 against the MiaPaCa-2 pancreatic cancer model with mutant K-ras, we encapsulated PH-427 into poly(lactic-co-glycolic acid) nanoparticles (PNP) to form drug-loaded PH-427-PNP. PH-427 showed a biphasic release from PH-427-PNP over 30 days during studies in sodium phosphate buffer, and in vitro studies revealed that the PNP was rapidly internalized into MiaPaCa-2 tumor cells, suggesting that PNP can improve PH-427 delivery into cells harboring mutant K-ras. In vivo studies of an orthotopic MiaPaCa-2 pancreatic cancer model showed reduced tumor load with PH-427-PNP as compared with treatment using PH-427 alone or with no treatment. Ex vivo studies confirmed the in vivo results, suggesting that PNP can improve drug delivery to pancreatic cancer harboring mutant K-ras. Keywords: nanoparticles, pancreatic cancer, AKT, bioluminescence imaging, drug delivery


  • Abstract 1426: Fumarate hydratase and deuterium depletion control oncogenesis via NADPH-dependent reductive synthesis: mitochondrial matrix water, DNA deuteration and epigenetic events

    by László G. Boros, Emmanuelle J. Meuillet, Ildikó Somlyai, Gábor Jancsó, György Jákli, Krisztina Krempels, László G. Puskás, István L. Nagy, Miklós Molnár, Keith R. Laderoute, et al.

    Clear cell kidney tumors become exclusively oxidative pentose cycle, hence cytoplasmic free water dependent by fumarate hydratase mutations, which disrupts the use of low deuterium containing metabolic water of the mitochondrial matrix and consumes pentose cycle-derived NADPH for reductive carboxylation [Yang Y., et al. PLoS One 8: e72179 (2013); Mullen AR, et al. Nature 481: 385-8, (2011)]. Metabolic water by complete fat oxidation, coupled with cytochrome-c, contains low average ∼115 ppm (parts per million) deuterium due to deuterium discrimination by plant lipogenic enzymes during photosynthesis. We herein report that mono-deuterated, 100 ppm, 50 ppm and 25 ppm extracellular (free) water treatment significantly decrease nucleotide and nuclear membrane behenic- and lignoceric acid synthesis in comparison with natural 150 ppm deuterium containing water via the oxidative branch of the pentose cycle in breast (MCF7) and lung (H441) cancer cell cultures, which recapitulates metabolism after genetically restored mitochondrial fumarate hydratase function in clear cell kidney tumors. Targeted [1,2-13C2]-D-glucose to [1-13C1]-D-ribose and 13C-glutamate fate associations indicate that the serine synthesis, one-carbon (folate) metabolism and the glycine cleavage (SOGC) pathway [Tedeschi PM, et al. Cell Death Dis 4: e877, (2013)] also mediates the metabolic control of deuterium depletion in MIA-PaCa pancreatic adenocarcinoma cells. We conclude that impaired mitochondria are involved in cell transformation by limiting the low natural deuterium containing complete fatty acid oxidation product, metabolic water, to enter nuclear membranes and nucleotides via reductive synthesis. In turn, “heavy” natural water and sugar dependent NADPH production taken over by the oxidative branch of the pentose cycle, as well as the SOGC-pathway, are deuterium loading “ticking time bombs” with a strong isotope effect and thus oncogenic epigenetic events that include unstable hydrogen bonds, aneuploidy in DNA structures and chemically altered methylation sites with severely disrupted gene expression patterns. Nevertheless, extra-mitochondrial NADPH synthesis opens a therapeutic window for deuterium depleted water to maintain and/or restore normal cellular functions. Our study provides a novel mechanism regarding lipid based ketogenic diets in the presence of hyperbaric oxygen treatment to decrease metastasis formation by producing low deuterium metabolic water via complete oxidation to prevent DNA, histone and nuclear membrane deuteration during NADPH dependent reductive synthesis. Citation Format: László G. Boros, Emmanuelle J. Meuillet, Ildikó Somlyai, Gábor Jancsó, György Jákli, Krisztina Krempels, László G. Puskás, István L. Nagy, Miklós Molnár, Keith R. Laderoute, Patricia A. Thompson, Gábor Somlyai. Fumarate hydratase and deuterium depletion control oncogenesis via NADPH-dependent reductive synthesis: mitochondrial matrix water, DNA deuteration and epigenetic events. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1426. doi:10.1158/1538-7445.AM2014-1426


  • Abstract 1434: Metformin-induced metabolic changes are k-ras-dependent in animal models of pancreatic cancer

    by Mary J. Cantoria, Laszlo G. Boros, Hitendra Patel, Haiyong Han, Natalia Ignatenko, Emmanuelle J. Meuillet

    Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy, that is very difficult to treat. To date, systemic treatment for PDA, either a single agent or combinations of agents, has shown only modest benefits. Numerous epidemiological studies have reported that metformin (MET), a widely used anti-diabetic drug, provides protective benefits in reducing PDA risk among the diabetic population. Using a stable isotope glucose (GLUC) tracer for dynamic metabolic profiling (SiDMAP), we recently reported that high cholesterol (CHOL) alters the cellular metabolism of MiaPaCa2 (a PDA cell line harboring mutant K-Ras) cells by redirecting glucose-derived acetyl-CoA toward fatty acid (FA) synthesis. This response to MET is depended on the level of intracellular CHOL synthesis. We now performed a SiDMAP study in the LSL-K-RasG12D/+, LSL-Trp53R172H/+, Pdx-1-Cre (KPC) and the LSL-K-RasG12D/+, Pdx-1-Cre (KC) mouse models for PDA, and their wild-type littermates (C57Bl6.129). The mice were treated (or not) with MET (250 mg/kg, i.p. Q5D) and subjected to an Intra Peritoneal GLUC Tolerance Test (IPGTT) pre- and post-MET treatment. The KPC mice with the average tumor volume of 80.83+8.57 mm3 and the KC mice with PanIN lesions (aver. 9 mo old) were put on study. K-Ras mutation, with the presence of the tumor (KPC mice), induced an increase in plasma GLUC production via de novo synthesis by the liver using futile cycling of GLUC derived lactate and pyruvate. MET treatment decreased this flux in mutated (KC) and tumor-bearing animals (KPC), but increased this flux in liver of control mice. MET treatment increased the complete GLUC oxidation into 13CO2 in the pancreas of KC and KPC animals. This indicates that the pancreas in MET-treated animals use less GLUC for RNA, DNA and FA synthesis. For 13CO2 production, we found that tumor growth has to be established; the mutation is not enough to induce changes in this flux. As in plasma, tumor growth increases pancreas lactate production from GLUC. MET treatment dramatically decreased the Warburg effect in the pancreas of mutated (KC) and mutated/tumor-bearing (KPC) mice. Finally, MET decreased GLUC-derived acetyl-CoA delivery to FAS and palmitate in control, mutated and tumor-bearing mice. Immunohistochemical analysis of the tumors from the KPC mice revealed that treatment with MET decreased the staining of phospho-Ser79-ACC by ∼54%, total FAS staining (mainly in the tumor stroma) by ∼43%, and the growth-associated transcription factor HMGA2 by ∼36.7%. These decreases correlated with a decrease in Ki67 staining by almost 80%, indicative of an inhibitory effect of MET on PDA growth. These results suggest that mutant K-Ras is responsible for the metabolic adaptation in both the tumor- (KPC) and non-tumor-bearing animals (KC). Our findings provide a strong rationale for targeting the metabolic changes induced by activated K-RAS in PDA patients which harbor mutations in K-RAS gene in >95% of cases.

  • Open Access

    Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells

    by Mary Jo Cantoria, László G. Boros, Emmanuelle J. Meuillet

    Metformin, a generic glucose lowering drug, inhibits cancer growth expressly in models that employ high fat/cholesterol intake and/or low glucose availability. Here we use a targeted tracer fate association study (TTFAS) to investigate how cholesterol and metformin administration regulates glucose-derived intermediary metabolism and macromolecule synthesis in pancreatic cancer cells. Wild type K-ras BxPC-3 and HOM: GGT(Gly) → TGT(Cys) K12 transformed MIA PaCa-2 adenocarcinoma cells were cultured in the presence of [1,2-13C2]-d-glucose as the single tracer for 24 h and treated with either 100 μM metformin (MET), 1 mM cholesteryl hemisuccinate (CHS), or the dose matching combination of MET and CHS (CHS–MET). Wild type K-ras cells used 11.43 % (SD = ±0.32) of new acetyl-CoA for palmitate synthesis that was derived from glucose, while K-ras mutated MIA PaCa-2 cells shuttled less than half as much, 5.47 % [SD = ±0.28 (P < 0.01)] of this precursor towards FAS. Cholesterol treatment almost doubled glucose-derived acetyl-CoA enrichment to 9.54 % (SD = ±0.24) and elevated the fraction of new palmitate synthesis by over 2.5-fold in MIA PaCa-2 cells; whereby 100 μM MET treatment resulted in a 28 % inhibitory effect on FAS. Therefore, acetyl-CoA shuttling towards its carboxylase, from thiolase, produces contextual synthetic inhibition by metformin of new palmitate production. Thereby, metformin, mutated K-ras and high cholesterol each contributes to limit new fatty acid and potentially cell membrane synthesis, demonstrating a previously unknown mechanism for inhibiting cancer growth during the metabolic syndrome.